Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Top Cited Papers
- 13 April 2016
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 60, 210-225
- https://doi.org/10.1016/j.ejca.2016.02.024
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete RemissionJournal of Clinical Oncology, 2012
- Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patientAnnals of Oncology, 2011
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for MelanomaJournal of Immunotherapy, 2009
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma PatientDermatology, 2009
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007